PROTAC oncology pipeline is transitioning from concept to commercial reality

Reading the signal

Targeted protein degradation uses bivalent small molecules (PROTACs) or monovalent molecular glues to recruit cellular degradation machinery (typically the ubiquitin-proteasome system) to a target protein, marking it for destruction rather than inhibiting its function. The mechanism is mechanistically distinct from conventional inhibitor pharmacology and offers theoretical access to targets that traditional inhibitor design cannot reach.

The pipeline status as of mid-2026:

• AR-degrader programs in prostate cancer have multiple late-stage assets, with pivotal readouts in second-generation androgen-receptor-resistant disease
• BRD4 and other epigenetic-target degrader programs in haematology and solid tumour indications
• KRAS-targeted degrader programs as a complement and competitor to the KRAS-G12C inhibitor class
• Oncogenic transcription factor and scaffold-protein degrader programs targeting indications historically considered undruggable

The commercial-grade pivotal readouts are the threshold the field is now approaching. The early-clinical data have been promising on response rates and on durability in resistant settings, but the move to phase 3 is where the modality establishes commercial reality.

Commercial implications

For sponsors of targeted protein degradation programs and adjacent oncology pipeline:

1. The first commercial PROTAC approval will reshape the modality's investment thesis. A successful pivotal readout in a high-value indication (prostate, breast, lymphoma) validates the modality and accelerates capital flow into the pipeline
2. The mechanism-class differentiation question is open. PROTACs versus molecular glues, different E3 ligase recruitment strategies, oral versus injection-route formulations all represent commercial-positioning choices that early commercial assets will define
3. Adjacent therapeutic areas will benefit from the oncology learnings. Targeted protein degradation in immunology, neuroscience, and rare disease pipelines will inherit the regulatory pathway and the manufacturing-capacity learnings from oncology

What we are watching

• Late-stage pivotal trial readouts in 12 to 24 months across the AR, KRAS, and BRD4 programmes
• First commercial-launch operating model: pricing, access, and indication framing for the pioneer asset
• Manufacturing-capacity development for the modality, particularly for the more complex bivalent PROTACs